Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J REALITI-N: Real-world effectiveness of mepolizumab in CRSwNP in Japan
jRCT1031250132Not yet recruiting
- Sponsor
- GSK
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by GSK. Primary endpoint: Change in SNOT-22 total score from baseline to 12 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
mepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on jRCT1031250132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250132.